Trial
NCT06926985
An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Jieyang People's Hospital
Collaborators
—
Condition
IgA Nephropathy (IgAN)
Intervention
anti-CD19/BCMA CAR NK cells
Why stopped
Due to limitation of production capacity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-04